Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Stopped early · Phase 3

Conditions studied: Chronic Kidney Disease, Secondary Hyperparathyroidism

In brief

The primary objective was to evaluate the efficacy of cinacalcet for reducing the plasma intact parathyroid hormone (iPTH) level by ≥ 30%.

Key facts

Study ID
NCT02138838
Run by
Amgen
People needed
55
Starts
2014-11-07
Expected to finish
2016-06-23
Last updated by the study team
2020-06-29

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.